Table 1

Baseline characteristics of the entire study population and according to the presence or absence of MACE, which was the composite endpoint

VariablesTotalMACE absentMACE presentp Value
Number955694 (72.7)261 (27.3)
Aldosterone (pmol/l)*997.3 (499.3–1785.7)950.4 (474.3–1700.0)1150.1 (578.1–2064.2)0.0118
Age66.5 (12.8)64.3 (12.4)72.3 (11.7)<0.0001
Male667 (69.8%)510 (73.5%)157 (60.2%)<0.001
Female288 (30.2%)184 (26.5%)104 (39.9%)<0.001
Hypertension512 (53.6%)344 (49.6%)168 (64.4%)<0.001
Diabetes244 (25.6%)159 (22.9%)85 (32.6%)0.002
Previous CAD356 (37.3%)230 (33.1%)126 (48.3%)<0.001
Smoking history410 (43.0%)318 (45.9%)92 (35.4%)0.004
STEMI398 (41.7%)285 (41.1%)113 (43.3%)0.534
eGFR (ml/min/1.73 m2)66.2 (19.9)69.4 (18.8)57.6 (20.6)<0.0001
Killip Class >1376 (39.6%)225 (32.7%)151 (58.1%)<0.001
Heart failure41 (4.3%)28 (4.0%)13 (5.0%)0.520
NTproBNP(pmol/l)*768.4 (255.2–2259.9)591.2 (182.2–1591.1)2036.1 (568.8–3908.4)<0.0001
ACEI or ARB766 (80.2%)576 (83.0%)190 (72.8%)<0.001
Betablockers757 (79.3%)574 (82.7%)183 (70.1%)<0.001
Diuretics244 (25.6%)141 (20.3%)103 (39.7%)<0.001
Statins811 (84.9%)614 (88.5%)197 (75.5%)<0.001
Aspirin803 (84.0%)601 (86.6%)202 (77.4%)0.001
GRACE score151.2 (39.8)143.6 (36.6)171.9 (41.1)<0.0001
  • Values are mean (SD) or number (%), except for aldosterone and NTproBNP which are median and IQR.

  • *Median and IQR.

  • ARB, angiotensin receptor blocker; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; MACE, major adverse cardiovascular events; NTproBNP, N-terminal pro-B type natriuretic peptide; STEMI, ST elevation myocardial infarction; GRACE, global registry of acute coronary events.